Background: To assess the prevalence of risk factors as determinants of intracranial atherosclerosis (IATH)-related stroke in a multi-ethnic community-based cohort. Methods: The Northern Manhattan Stroke Study included a population-based incidence study and a nested case-control study. Incident cases of first ischemic stroke were 1:2 when matched to community controls by age, sex, and race/ethnicity. Vascular risk factors were assessed among controls and compared against the following stroke subtypes: IATH, extracranial atherosclerosis (EATH), and non-atherosclerotic (NATH: cardioembolic, lacunar, and cryptogenic). Conditional logistic-regression was used to determine the association between risk factors and stroke subtypes. Results: The crude incidence of IATH was 8/100,000 per year and the relative incidence of IATH was higher than that of EATH in blacks (5.9 vs. 3.2/100,000 per year) and in Hispanics (5.0 vs. 1.7/100,000 per year). The IATH group had a higher prevalence of diabetes mellitus (DM; 67% IATH, 60% EATH, 48% NATH, and 23% controls; p < 0.05 IATH vs. control) and of metabolic syndrome (62% IATH, 40% EATH, 40% NATH, and 35% controls; p < 0.05 IATH vs. control). In multivariate analysis, DM conferred a higher risk for IATH versus NATH stroke (OR, 10.8; 95% CI, 2.0–57 vs. OR, 2.7; 95% CI, 1.9–3.9; p < 0.05) and much lower for EATH (OR, 6.2; 95% CI, 1.2–32). The metabolic syndrome conferred a higher risk for IATH stroke subtype (OR, 4.6; 95% CI, 1.1–18.7) when compared to EATH (OR, 2.3; CI, 0.6–9.1) and NATH (OR, 2.4; CI, 1.7–3.3). Conclusions: DM is a more important determinant for IATH-related stroke than EATH or NATH.

Keywords:
Atherosclerosis, Ischemic stroke, Metabolic syndrome, Diabetes mellitus
1.
Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. The EC/IC bypass study group. N Engl J Med 1985;313:1191–1200.
2.
Sacco RL, Kargman DE, Gu Q, Zamanillo MC: Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: the Northern Manhattan Stroke Study. Stroke 1995;26:14–20.
3.
White H, Boden-Albala B, Wang C, Elkind MS, Rundek T, Wright CB, Sacco RL: Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation 2005;111:1327–1331.
4.
Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, Litt B: Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 1996;27:1974–1980.
5.
Bang OY, Kim JW, Lee JH, Lee MA, Lee PH, Joo IS, Huh K: Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology 2005;65:296–298.
6.
Feldmann E, Daneault N, Kwan E, Ho KJ, Pessin MS, Langenberg P, Caplan LR: Chinese-white differences in the distribution of occlusive cerebrovascular disease. Neurology 1990;40:1541–1545.
7.
Sacco RL, Kargman DE, Zamanillo MC: Race-ethnic differences in stroke risk factors among hospitalized patients with cerebral infarction: The Northern Manhattan Stroke Study. Neurology 1995;45:659–663.
8.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
9.
Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM, Clearfield M: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4s) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS). Am J Cardiol 2004;93:136–141.
10.
Boden-Albala B, Sacco RL, Lee HS, Grahame-Clarke C, Rundek T, Elkind MV, Wright C, Giardina EG, DiTullio MR, Homma S, Paik MC: Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 2008;39:30–35.
11.
Sacco RL, Elkind M, Boden-Albala B, Lin IF, Kargman DE, Hauser WA, Shea S, Paik MC: The protective effect of moderate alcohol consumption on ischemic stroke. JAMA 1999;281:53–60.
12.
Sacco RL, Gan R, Boden-Albala B, Lin IF, Kargman DE, Hauser WA, Shea S, Paik MC: Leisure-time physical activity and ischemic stroke risk: The Northern Manhattan Stroke Study. Stroke 1998;29:380–387.
13.
Special report from the National Institute of Neurological Disorders and Stroke. Classification of Cerebrovascular Diseases III. Stroke 1990;21:637–676.
14.
Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, Paik MC, Hauser WA: Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol 1998;147:259–268.
15.
Race and Ethnic Standards for Federal Statistics and Administrative Reporting (Directive No. 15). Office of Management and Budget, Federal Register, 1978, vol 43, p 19269.
16.
Adams HP Jr, Woolson RF, Clarke WR, Davis PH, Bendixen BH, Love BB, Wasek PA, Grimsman KJ: Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Control Clin Trials 1997;18:358–377.
17.
Sacco RL, Roberts JK, Boden-Albala B, Gu Q, Lin IF, Kargman DE, Berglund L, Hauser WA, Shea S, Paik MC: Race-ethnicity and determinants of carotid atherosclerosis in a multiethnic population: the Northern Manhattan Stroke Study. Stroke 1997;28:929–935.
18.
Gorelick PB, Caplan LR, Hier DB, Patel D, Langenberg P, Pessin MS, Biller J, Kornack D: Racial differences in the distribution of posterior circulation occlusive disease. Stroke 1985;16:785–790.
19.
Inzitari D, Hachinski VC, Taylor DW, Barnett HJ: Racial differences in the anterior circulation in cerebrovascular disease: how much can be explained by risk factors? Arch Neurol 1990;47:1080–1084.
20.
Sacco RL, Boden-Albala B, Abel G, Lin IF, Elkind M, Hauser WA, Paik MC, Shea S: Race-ethnic disparities in the impact of stroke risk factors: the Northern Manhattan Stroke Study. Stroke 2001;32:1725–1731.
21.
Qureshi AI, Safdar K, Patel M, Janssen RS, Frankel MR: Stroke in young black patients: risk factors, subtypes, and prognosis. Stroke 1995;26:1995–1998.
22.
Williams AO, Resch JA, Loewenson RB: Cerebral atherosclerosis – a comparative autopsy study between Nigerian negroes and American negroes and Caucasians. Neurology 1969;19:205–210.
23.
Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies. Part I. Circulation 2003;108:1664–1672.
24.
Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS: Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42–46.
25.
McNeill AM, Rosamond WD, Girman CJ, Heiss G, Golden SH, Duncan BB, East HE, Ballantyne C: Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (the ARIC study). Am J Cardiol 2004;94:1249–1254.
26.
Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL: The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004;25:342–348.
27.
Scuteri A, Najjar SS, Muller DC, Andres R, Hougaku H, Metter EJ, Lakatta EG: Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol 2004;43:1388–1395.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.